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and Edward W. Tate‡
AMPylation of mammalian small GTPases by bacterial
virulence factors can be a key step in bacterial infection of
host cells, and constitutes a potential drug target. This
posttranslational modification also exists in eukaryotes,
and AMP transferase activity was recently assigned to
HYPE Filamentation induced by cyclic AMP domain con-
taining protein (FICD) protein, which is conserved from
Caenorhabditis elegans to humans. In contrast to bacte-
rial AMP transferases, only a small number of HYPE sub-
strates have been identified by immunoprecipitation and
mass spectrometry approaches, and the full range of tar-
gets is yet to be determined in mammalian cells. We de-
scribe here the first example of global chemoproteomic
screening and substrate validation for HYPE-mediated AM-
Pylation in mammalian cell lysate. Through quantitative
mass-spectrometry-based proteomics coupled with novel
chemoproteomic tools providing MS/MS evidence of AMP
modification, we identified a total of 25 AMPylated proteins,
including the previously validated substrate endoplasmic
reticulum (ER) chaperone BiP (HSPA5), and also novel sub-
strates involved in pathways of gene expression, ATP bio-
synthesis, and maintenance of the cytoskeleton. This data-
set represents the largest library of AMPylated human
proteins reported to date and a foundation for substrate-
specific investigations that can ultimately decipher the
complex biological networks involved in eukaryotic
AMPylation. Molecular & Cellular Proteomics 15: 10.1074/
mcp.O115.054429, 715–725, 2016.
Covalent posttranslational modification (PTM) of hydroxyl-
containing amino acids in proteins by adenosine monophos-
phate (AMP), called AMPylation or adenylylation, was first
discovered almost a half century ago as a mechanism con-
trolling the activity of bacterial glutamine synthetase (1). This
unusual PTM was unknown in eukaryotes until it was identi-
fied in 2009 in the context of bacterial infection, when Yar-
brough et al. reported AMPylation of host small GTPases by
bacterial virulence factor Vibrio outer protein S (VopS) from
Vibrio parahemeolyticus. In this context, AMPylation pre-
cludes interactions with downstream binding partners and
causes actin cytoskeleton collapse leading to cell death (2).
Since then, the field of AMPylation has grown substantially,
with reports describing AMPylation activity of other bacterial
effectors, like Immunoglobulin binding protein A (IbpA) in His-
tophilus somni (3) and Defects in Rab1 recruitment protein
A (DrrA) in Legionella pneumophila (4). These new bacterial
AMPylators share a common substrate class (small GTPases);
however, they differed in the identity of their catalytic residues
and architecture of their active sites. Accordingly, bacterial
AMP transferases have been classified as either filamentation
induced by cyclic AMP (FIC) or adenylyl transferase (AT)1
domain containing enzymes, with catalytic His or Asp resi-
dues, respectively.
Although adenylylation has been most extensively de-
scribed in the context of bacterial infection, there is a growing
interest in elucidating the scope of this PTM in a native eu-
karyotic context. Among the ca. 3000 FIC proteins identified
so far by sequence alignment, only a single enzyme has been
identified in eukaryotes: Huntingtin-associated protein E
(HYPE), also known as FICD. HYPE is conserved from C.
elegans to humans, and mRNA expression data suggest that
it is present at low levels in all human tissues (3). Apart from
the catalytic FIC domain, the protein consists of one trans-
membrane helix and two tetratricopeptide repeat motifs that
point to localization at a membrane and amenability toward
protein–protein interactions, respectively. We recently added
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to this picture by solving the first crystal structure of Homo
sapiens HYPE (5), illustrating that the only human FIC is
substantially different from its bacterial cousins (6, 7). HYPE
was shown to form stable asymmetric dimers supported by
the extended network of contacts exclusive to the FIC do-
mains, while the tetratricopeptide repeat motifs have a more
flexible arrangement and appear to be exposed for protein–
protein interactions in the vicinity of the membrane. In addi-
tion, we confirmed the similarity of the active site architecture
to other FIC proteins for which a crystal structure is available,
with the catalytic loop comprising the invariant catalytic His363
(8), and further substantiated the role of a critical residue
Glu234 in an inhibitory helix (9) that may be responsible for
regulating HYPE enzymatic activity.
Various catalytic activities have been demonstrated for FIC
proteins, including nucleotide (AMP, GMP, and UMP) transfer
as well as phosphorylation and phosphocholination (10–13).
We and others (3, 5, 14, 15) have demonstrated that HYPE
can function in protein AMPylation, although the activity of the
wild-type (WT) enzyme is very weak, consistent with active
site obstruction by Glu234. It is hypothesized that this intra-
molecular inhibition can be relieved by specific but as yet
unknown protein–protein interactions or by the removal of the
conserved Glu. Indeed, the E234G mutation substantially
boosts HYPE’s activity as demonstrated by the elevated auto-
AMPylation of HYPE itself (5, 9) and a few of its recently
reported substrates, including the ER chaperone BiP in vivo
(14, 15) and several histone proteins in vitro (16, 17). HYPE
activity was initially implicated in visual neurotransmission in
flies (18) and later in regulation of the unfolded protein re-
sponse (UPR) in transfected cells, although there is limited
consensus over the mechanism (14, 15). Most recently, it has
been proposed that HYPE activity might have a role in regu-
lation of gene expression; however, the mechanistic details
remain to be elucidated (17).
AMPylation profiling is not a trivial task (19), and several
strategies have emerged over the past few years ranging from
labeling with radioactive ATP (2, 3) and immunoprecipitation
with AMPylation-specific antibodies (20, 21) to mass spec-
trometry (MS) approaches focused on AMP fragmentation
(22, 23). Although these methods contributed significantly to
developments in the field, they also suffer from certain draw-
backs, including low sensitivity, high background, limited
quantitative power, and limited amenability to high-through-
put (HT) substrate identification. In contrast, chemoproteomic
strategies involving application of substrate analogues (sub-
strate probes) equipped with small and inert chemical handles
in combination with sensitive detection by MS can facilitate
rapid visualization and/or robust enrichment of modified pro-
teins and can provide superior performance in HT profiling of
numerous challenging PTMs (24). AMPylation-specific sub-
strate probes have been developed, and their robust perform-
ance was evaluated in vitro, albeit to date only in the context
of bacterial effector-mediated AMPylation (25–27). We previ-
ously showed that a bioorthogonal substrate probe (26) is well
tolerated in the active site of human HYPE and, moreover, that
it has potential for chemoproteomic profiling of HYPE sub-
strates in vitro when combined with ligation through copper-
catalyzed azide alkyne cycloaddition (CuAAC) to a dedicated
capture reagent decorated with a biotin affinity handle and
carboxytetramethylrhodamine (TAMRA) fluorophore (5).
Herein, we present the first global AMPylation profile in a
native eukaryotic context utilizing a bioorthogonal ATP ana-
logue and chemoproteomic methodology. We first demon-
strate efficient enrichment and fast visualization of potential
HYPE substrates in cell lysates by in-gel fluorescence, fol-
lowed by robust identification via shotgun proteomics on a
QExactive mass spectrometer. Furthermore, we extensively
validate candidate substrates via HYPE titration and ATP
competition experiments with a quantitative MS-based read-
out, as well as Western blotting and direct MS/MS evidence
for AMP modification. Finally, we analyze HYPE interaction
partners in vivo, providing a link between our discoveries in
lysates and a physiologically relevant context, delivering the
first experimentally validated library of HYPE substrate
proteins.
MATERIALS AND METHODS
General—Culture media and reagents for cell culture were ob-
tained from Sigma Aldrich Ltd, Dundee Cell Products (Dundee, UK),
and Gibco (Life Technologies Inc.). Yn-6-ATP was from Jena Biosci-
ence (Jena, Germany) and Az-TB was synthesized as described (28).
All CuAAC reagents (CuSO4, Tris (2-carboxyethyl phosphine) (TCEP),
Tris (benzyltriazolylmethyl)amine (TBTA), buffer salts, ATP, DTT, and
iodoacetamide were from Sigma Aldrich. EDTA-free complete prote-
ase inhibitor was obtained from Roche Diagnostics Ltd. Primary and
secondary antibodies were from Abcam (Cambridge, UK) and Santa
Cruz Biotechnology Inc. Absorbance in 96-well plates was measured
using a SpectraMax M2/M2e Microplate Reader from Molecular De-
vices LLC. For proteomics, all buffers were filtered using a 0.2 m
filter. Low binding tubes (Protein LoBind tubes, Eppendorf, UK) were
used to carry out the enrichment of proteins for MS-based proteom-
ics. Sequencing grade Trypsin was obtained from Promega Corp.
(Madison, WI).
Cloning and Protein Expression—Plasmid pcDNA-DEST40-HYPE-
Bio, encoding HYPE WT-bio was prepared by cloning the biotinyla-
tion tag encoding the amino acid residues GLNDIFEAQKIEWHE at the
COOH terminus of wild-type HYPE. This ORF was then cloned into
the Gateway (Life Technologies) vector pcDNA-DEST40 and verified
by sequencing. Plasmid pICC1394 encoding GFP-BirA was obtained
as described in Mousnier et al. (29). Recombinant protein expression
was performed as described previously (5). Briefly, HYPE constructs
in a in-Fusion enabled, pET28a-based vector for expression of HIS6-
SUMO-POI in E. coli (pOPINS) (OPPF, Oxford Protein Production
Facility, UK) vector background were transformed into C41(DE3)
(Lucigen Corp., Middleton, WI) and grown up in 2xYT medium at
37 °C. Cultures were cooled to 20 °C and subsequently induced with
0.1 mM isopropyl -D-1-thiogalactopyranoside. Cultures were har-
vested after 16 h and frozen prior to purification (please see (5) for
details).
Cell Culture and Lysis—HEK293 cells were grown in DMEM sup-
plemented with 10% FBS in a humidified 10% CO2-containing atmo-
sphere at 37 °C. For SILAC (30, 31) experiments, cells were grown as
described above in R0K0 (light) and R10K8 (heavy) DMEM supple-
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mented with dialyzed FBS, allowing10 doublings to ensure efficient
(97%) incorporation of labeled amino acids. Cell lysis was per-
formed on ice using AMPylation buffer (20 mM Hepes, pH 7.4, 100 mM
NaCl, 5 mM MgCl2, 1% Triton X-100, 1 x EDTA-free complete prote-
ase inhibitor) and sheer stress. Lysates were kept on ice for 20 min
and centrifuged at 17,000 g for 20 min to remove insoluble material.
Supernatants were collected and stored at 80 °C. Protein concen-
tration was determined using the Bio-Rad DC Protein Assay.
In Vitro AMPylation, CuAAC and Enrichment—AMPylation in cell
lysates (2 mg/ml) was carried out in AMPylation buffer supplemented
with DTT (1 mM), Yn-6-ATP (100 M) and  recombinant AMPylators
(1/10 w/w enzyme to total protein) for 3 h at 30 °C. AMPylation was
stopped by protein precipitation (chloroform/methanol, 0.25:1, rela-
tive to the sample volume). Precipitates were isolated by centrifuga-
tion (17, 000  g; 10 min), washed once with methanol (400 l), and
air dried (10 min). Dried pellets were then reconstituted (PBS, 0.4%
SDS) at 2 mg/ml, and the CuAAC mixture was prepared by adding
reagents in the following order and by vortex mixing between the
addition of each reagent: Az-TB (final concentration 0.1 mM), CuSO4
(final concentration 1 mM), TCEP (final concentration 1 mM), and TBTA
(final concentration 0.1 mM). Following the addition of the CuAAC
mixture, the samples were vortexed (room temperature, 1 h), and the
reaction was stopped by addition of EDTA (final concentration 10
mM). Subsequently, proteins were precipitated, isolated and recon-
stituted (1 mg/ml) as described above. The samples were then added
to 15 l (per 100 g protein) of pre-washed (0.2% SDS in PBS (3 
500 l)) Dynabeads®MyOne™ Streptavidin C1 (Invitrogen Corp.) and
gently vortex mixed for 90 min. The supernatant was removed and the
beads were washed with 0.2% SDS in PBS (3  500 l).
SDS-PAGE, in-gel Fluorescence and Western Blotting—30 l of
2% SDS in PBS and 10 l 4x SLB (Invitrogen) were added to the
beads and 7 l SLB were added to 20 l of supernatant. The samples
were then boiled (10 min), centrifuged (1,000  g, 2 min) and loaded
on a 12% SDS-PAGE gel (supernatant: 13 l (10 g of proteins);
pull-down: 15 l (40 g of input proteins). Following electrophoresis
(60 min, 180V), the gel was washed with MilliQ (3x), soaked in fixing
solution (40% MeOH, 10% acetic acid, 50% water) for 5 min and
washed with water (3x). In-gel fluorescence was detected using an
Ettan DIGE Imager (GE Healthcare Uppsala, Sweden), and the protein
loading was checked by Coomassie staining. For Western blotting,
proteins were not fixed; instead, they were transferred onto PVDF
membranes using an iBlot device (Invitrogen) according to manufa-
cturer’s instructions. After brief washing with TBS-T (1 x TBS, 0.1%
Tween-20) membranes were blocked (5% milk, TBS-T, 1 h), washed
with TBS-T (3x) and incubated with primary antibodies (5% milk,
TBS-T, overnight, 4 °C) at supplier-recommended dilutions. Following
washing (TBS-T, 3x), membranes were incubated with secondary
antibodies (1:10,000, 5% milk, TBS-T, 1 h) and, after a final washing
step, treated with Luminata Crescendo Western HRP substrate (Mil-
lipore Darmstadt, Germany) for chemiluminescence imaging using a
LAS-3000 Imaging System (GE Healthcare). In case of biotin blots,
membranes were blocked with 3% BSA and incubated with strepta-
vidin-HRP in 0.3% BSA, TBS-T for 1 h.
Sample Preparation for MS-Based Proteomics—For SILAC-based
identification of HYPE candidate substrates in cell lysates, AMPyla-
tion was carried out separately in 0.2 mg of light (no enzyme control)
and 0.2 mg of heavy (various AMPylators) labeled HEK293 lysates as
described above. After 3 h at 30 °C, the lysates were mixed in 1:1 ratio
and proteins were immediately precipitated to quench the reaction.
Samples were prepared in biochemical triplicates. For HYPE titration
and ATP competition experiments, a “spike in” standard was pre-
pared by performing AMPylation reaction with HYPE E234G for 3 h at
30 °C as described above in a heavy-labeled HEK293 lysate. This
standard was then added in 1:2 ratio to light samples (0.2 mg each)
prepared analogously and supplemented with decreasing amounts of
HYPE E234G (1/10–1/1000 w/w enzyme to total protein) or increasing
amounts of ATP (0–1000 M) followed by immediate protein precip-
itation to quench the reaction. Those samples were prepared in
biochemical duplicates.
CuAAC and Enrichment for MS-Based Proteomics—After protein
reconstitution (2 mg/ml, 0.4%SDS in PBS), CuAAC was carried out as
described above followed by protein precipitation and final reconsti-
tution for substrate enrichment. NeutrAvidin agarose resin (Thermo
Fisher Scientific Inc.) was washed with 0.2% SDS in PBS (3x). The
samples were mixed with beads (25 l slurry/sample), and the en-
richment was carried out on a rotating wheel for 2 h at room temper-
ature. Following the removal of supernatants, the beads were sequen-
tially washed with 1% SDS in PBS (3x), 4 M urea in 50 mM AMBIC (2x),
and 50 mM AMBIC (5x). Protein digestion was initiated upon addition
of trypsin (ca. 1/1000 w/w protease to protein), and samples were
incubated overnight at 37 °C. The samples were then briefly centri-
fuged, diluted twice (aqueous 0.1% TFA), and stage-tipped according
to a published protocol (32). Elution from the sorbent (SDC-XC, from
3M Empore) with 70% acetonitrile in water was followed by speed-
vac-assisted solvent removal, reconstitution of peptides in 0.5% TFA,
2% acetonitrile in water, and finally sample transfer into LC-MS
sample vials.
Identification of HYPE Interactome In Vivo—HEK293 cells grown in
R10K8 or R0K0 DMEM supplemented with biotin (4 M) were reverse
transfected with equal amounts of WT-bio and BirA or BirA alone,
respectively, using TurboFect (Thermo Fisher Scientific) according to
the manufacturer’s instructions. After 18 h incubation, transfection
media were replaced by a fresh aliquot, and cells incubated for
additional 24 h. Next, cells were washed with PBS (2x) and lysed on
ice using the lysis buffer (PBS 1x, 0.5% Triton X-100, 1 x EDTA-free
complete protease inhibitor). Lysates were kept on ice for 20 min and
carefully centrifuged at 5000  g for 10 min only to remove insoluble
material. Supernatants were collected and kept on ice while protein
concentration was determined as described above. Heavy (WT-bio/
BirA) and light (BirA) lysates (120 g each) were used immediately to
maintain native protein interactions. The samples were enriched sep-
arately on NeutrAvidin beads for 1 h at room temperature and washed
carefully with the lysis buffer (4x) and 50 mM Ammonium bicarbonate
(AMBIC) (4x). The beads were then mixed in 1:1 ratio, proteins were
reduced (5 mM DTT, 30 min, 55 °C), alkylated (10 mM iodoacetamide,
30 min, in the dark), digested with trypsin, and processed for MS-
based proteomics as described above. Samples were prepared in
biological duplicates.
nLC-MS/MS and Data Analysis—The analysis was performed using
an Acclaim PepMap RSLC column 50 cm  75 m inner diameter
(Thermo Fisher Scientific) using a 2 h acetonitrile gradient in 0.1%
aqueous formic acid at a flow rate of 250 nl/min. Easy nLC-1000 was
coupled to a QExactive mass spectrometer via an easy-spray source
(all Thermo Fisher Scientific). The QExactive was operated in data-
dependent mode with survey scans acquired at a resolution of 75,000
at m/z 200 (transient time 256 ms). Up to 10 of the most abundant
isotope patterns with charge 2 or higher from the survey scan were
selected with an isolation window of 3.0 m/z and fragmented by HCD
with normalized collision energy of 25. The maximum ion injection
times for the survey scan and the MS/MS scans (acquired with a
resolution of 17 500 at m/z 200) were 20 and 120 ms, respectively.
The ion target value for MS was set to 106 and for MS/MS to 105, and
the intensity threshold was set to 8.3 102. The data were processed
with MaxQuant (33) (version 1.5.0.25), and the peptides were identi-
fied from the MS/MS spectra searched against human-referenced
(with isoforms) proteome (UniProt (34), October 2014, 41,917 entries)
using the Andromeda (35) search engine. SILAC-based experiments
in MaxQuant were performed using the built-in quantification algo-
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rithm (33) with minimal ratio count  2 and enabled “Match between
runs” option (time window 0.7 min) and “Re-quantify” feature. Cys-
teine carbamidomethylation was selected as a fixed modification
(protein–protein interaction experiments only) and methionine oxida-
tion and acetylation of protein N terminus as variable modifications.
For in silico digests of the reference proteome, the following peptide
bond cleavages were allowed: arginine or lysine followed by any
amino acid (a general setting referred to as Trypsin/P). Up to two
missed cleavages were allowed. The false discovery rate was set to
0.01 for peptides, proteins, and sites. Other parameters were used as
preset in the software (maximal mass error 4.5 ppm and 20 ppm for
precursor and product ions, respectively, minimum peptide length 
7, minimum razor  unique peptides  1, minimum scores for un-
modified and modified peptides  0 and 40, respectively). “Unique
and razor peptides” mode was selected to allow identification and
quantification of proteins in groups (razor peptides are uniquely as-
signed to protein groups and not to individual proteins). Data were
further analyzed using Microsoft Office Excel 2007 and Perseus (ver-
sion 1.5.0.9) as described in the Results section and in Supplemental
Tables S1-S3 and S6. Data are available via ProteomeXchange (iden-
tifier PXD002601).
Identification of AMPylated Peptides—AMPylation reaction was
carried out in 0.3 mg of light lysate supplemented with E234G in the
presence of Yn-6-ATP or ATP (control) as described above in bio-
chemical triplicates. Instead of the standard capture reagent (Az-TB),
a site ID reagent, Az-RTB (36), was applied for CuAAC under the
above-mentioned conditions. Enriched proteome was digested with
trypsin and analyzed by LC-MS/MS. Two injections per sample were
performed and data from the two LC-MS/MS runs processed to-
gether with PEAKS7 suite (37). Samples were searched against the
same UniProt Homo sapiens database that was used in MaxQuant
analyses. Trypsin (specific, up to three missed cleavages allowed)
was selected for database searches, and no enzyme was chosen in
de novo searches (up to five candidates per spectrum reported). The
maximal mass error was set to 10 ppm (de novo search) or 5 ppm
(database search) for precursor ions and 0.01 Da for product ions.
Methionine oxidation as well as the AMP-derived adduct (624.1918
Da) to Ser, Thr, and Tyr were set as variable modifications. The
maximal number of modifications per peptide was set as five. The
false discovery rate was set to 0.01 for peptides, and a minimum of
one unique peptide per protein was required.
Auto AMPylation of HYPE E234G (1 mg/ml) was carried out under
standard conditions using ATP (1 mM) as the AMP donor. The protein
was then precipitated, reconstituted in 50 mM AMBIC (0.5 mg/ml), and
trypsinized before LC-MS/MS and data analysis with PEAKS7 as
described above with the AMP adduct mass of 329.0525 Da. Data
are available via ProteomeXchange (identifiers PXD002601 and
PXD003053).
RESULTS
Screening HYPE Activity and Substrate Enrichment by In-
Gel Fluorescence—The process of chemoenzymatic tagging
(Fig. 1A) relies on enzymatic transfer of a chemical handle, a
so-called bioorthogonal reporter (usually an azide or an
alkyne), from a synthetic ATP analogue substrate, Yn-6-ATP
(Fig. 1B), onto substrate protein(s). This biotransformation is
followed by a nonenzymatic but highly chemoselective reac-
tion (CuAAC) to an appropriate ligation partner, or “capture
reagent” (Fig. 1C), to introduce secondary labels; a TAMRA
fluorophore and biotin affinity tag allow substrate detection
and enrichment, respectively. Importantly, chemoenzymatic
tagging introduces a covalent linkage between the chemical
tag and the modified protein (Fig. 1A), thus allowing far more
FIG. 1. Chemoenzymatic tagging strategy for AMPylome profiling. (A) Schematic representation of chemoenzymatic tagging of AMPy-
lation substrates in vitro. (B) Structure of the bioorthogonally tagged substrate analogue, Yn-6-ATP. (C) Structures of capture reagents Az-TB
and Az-RTB; Az - azide, T - TAMRA, B - biotin, R - arginine. (D) In-gel fluorescence imaging of enrichment efficiency for tested HYPE variants
(WT, H363A, E234G) and bacterial AMPylator, VopS.
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stringent washing following enrichment than is permitted by
immunoprecipitation approaches, leading to background re-
duction. We previously demonstrated that HYPE activity can
be efficiently visualized utilizing a chemoenzymatic strategy,
with Yn-6-ATP and a capture reagent, Az-TB (5). To test if the
methodology allows also for efficient enrichment of AMPy-
lated substrates, we first identified the optimal AMPylation
time for maximal labeling in lysate (3 h), and verified the probe
specificity in our system through competition against ATP
(Figs. S1A and S1B). We then performed AMPylation in
HEK293 lysate either without AMP transferase (negative con-
trol) or with one of a range of HYPE constructs, alongside the
well-characterized bacterial AMPylator VopS (positive con-
trol). As shown in Fig. 1D in the VopS-catalyzed reaction, we
observed robust enrichment of potential AMPylation sub-
strates clustered in the molecular weight range characteristic
for small GTPases. In contrast, HYPE-catalyzed AMPylation
resulted only in minimal enrichment for the WT and H363A
proteins, consistent with the autoinhibited and catalytically
inactive states of these HYPE variants, respectively. As in-gel
fluorescence labeling patterns of no-enzyme control, WT and
H363A HYPE are similar; the observed bands likely represent
background labeling (proteins bound nonspecifically either to
the enrichment beads or the ATP substrate analogue) and not
potential substrate proteins. Upon relief of inhibition through
E234G mutation, we observed a substantial increase in HYPE
activity that translated to efficient enrichment of several pro-
tein bands as shown in Fig. 1D. Importantly, we did not
observe any enrichment in the molecular weight range of
small GTPases, which points to substantially different sub-
strate specificities for bacterial and eukaryotic AMPylators.
Identification of Candidate HYPE Substrates In Vitro—Effi-
cient enrichment of substrate proteins is a crucial step in HT
profiling of PTMs. Upon confirmation of enrichment efficiency,
we implemented SILAC (30) shotgun proteomic experiments
to identify HYPE AMPylation substrates in HEK293 cell lysate
(Fig. S2). Cells cultured in heavy (R10K8) or light (R0K0)
DMEM media were lysed as described in the Methods sec-
tion. We then performed chemoenzymatic tagging with Yn-6-
ATP in triplicate either in the presence of AMPylators (WT,
E234G, VopS) or without enzyme (to account for potential
nonspecificity) in heavy or light lysate, respectively. Lysates
were mixed 1:1 and ligated to Az-TB by CuAAC, followed by
enrichment of the tagged proteome by biotin-NeutrAvidin pull
down, stringent washing, on-bead tryptic digestion, and anal-
ysis by shotgun proteomics on a nanoLC-QExactive mass
spectrometer platform. RAW files were analyzed with Max-
Quant software (33) as described in the Methods section, and
heavy/light (H/L) ratios were generated for each protein.
Quantification in at least two out of three replicates and all
log2 H/L ratios 1 were required as threshold for protein
assignments as potential AMPylation candidates. Applying
these criteria, we were pleased to observe that all five protein
IDs above this threshold in VopS-catalyzed AMPylation were
indeed the expected substrates, i.e. Rho family small
GTPases (Table S1). Following this experimental validation,
analogous thresholds were applied to HYPE-mediated AM-
Pylations. In the case of E234G, we assigned 102 candidate
substrates that matched these criteria from a total of 745
quantified proteins (Table S1). In the case of the WT protein,
however, candidate substrates could not be assigned as all of
the 616 quantified proteins were below the selected enrich-
ment threshold (Table S1).
Candidate Substrate Validation through Quantitative Com-
petition Experiments and Immunoblotting—Although the de-
sign of the SILAC experiments above can select against false
positive IDs originating from nonspecific interactions, it is
important to note that HYPE-specific enrichment cannot ex-
clude ATP-independent false discoveries as a result of tightly
interacting substrate binding partners. To elevate the confi-
dence of our identifications in terms of both HYPE and ATP
specificity, we combined spike-in SILAC quantification (31)
with HYPE titration and with ATP competition experiments
(Fig. 2A). A spike-in standard, generated by performing
AMPylation in the presence of HYPE E234G and Yn-6-ATP in
heavy HEK293 lysate, was spiked in a 1:2 ratio into samples
prepared analogously in the light lysate in the presence of
either decreasing amounts of HYPE E234G or increasing
amounts of ATP (five conditions in duplicate per experiment).
Spiked samples were ligated to Az-TB, enriched, and sub-
jected to digest and proteomic analysis, as described above.
Quantification in 6 out of 10 samples (two replicates of five
conditions) as well as a dose-dependent response 50%
were set as specific thresholds. Application of these criteria to
the 102 candidate substrates revealed robust response to
HYPE titration for 34 proteins (Table S2), providing strong
evidence for HYPE-specific enrichment, while 47 candidate
substrates displayed high sensitivity toward competition with
the natural substrate, ATP (Table S3). This double selection
scenario accounting for both HYPE and ATP enrichment
specificity delivered a pool of 25 high confidence substrates
(Fig. 2B), including the previously reported ER chaperone BiP
(HSPA5). Subsequently, several novel high-confidence sub-
strates were cross-checked by a traditional immunoblotting
approach, where protein-specific antibodies were applied to
samples enriched in a HYPE-dependent manner (Fig. 2C).
Identification of AMPylation Sites—MS-based approaches
for the identification of AMPylated peptides (22, 23) take
advantage of characteristic fragmentation patterns of the
AMPmoiety that upon collision-induced dissociation give rise to
several well-established diagnostic ions. Although the meth-
odology has the potential to scan AMPylated peptides in
complex protein mixtures, this feature has not been further
explored. We decided to couple the confidence arising from
the presence of AMP-characteristic ions with the HT feature
of the chemoenzymatic approach and the site ID capture
reagent, Az-RTB (Fig. 1C), previously developed in our labo-
ratory for confident PTM site identification (36, 38). In contrast
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to Az-TB and owing to the presence of an Arg residue,
Az-RTB enables facile release of modified peptides from Neutr-
Avidin beads during on-bead tryptic digestion (Fig. S3). AM-
Pylation reactions were performed in HEK293 lysate supple-
mented with E234G and either Yn-6-ATP or ATP (control) in
triplicate, followed by CuAAC ligation to Az-RTB, substrate
enrichment, trypsinization, and shotgun proteomic analysis.
RAW files were analyzed with the PEAKS7 suite (37) for the
presence of an adduct derived from Yn-6-AMP coupled with
AzRTB (Fig. 3A) on Ser, Thr, and Tyr residues, and spectra
were manually inspected for their quality and the presence of
diagnostic ions (Fig. 3A). In six samples analyzed in technical
duplicate, we observed 115 peptide spectrum matches (Table
S4) of which 30 did not contain at least two of three diagnostic
ions and were therefore excluded. The remaining 85 peptide
spectrum matches were found exclusively in Yn-6-ATP
treated samples and matched 23 AMPylated peptides on 11
proteins. These 23 peptides were inspected further and di-
vided into high and lower confidence annotations based on
representation across triplicate samples (Table S4). Subse-
quent stringent manual examination of MS/MS fragmentation
from the high-confidence group returned five AMPylation
sites on four proteins (Fig. 3B and Fig. S4), including HYPE
itself and proteins from the pool of 25 high-confidence sub-
strates (HSPA5, EEF1A1, TUBB4B). We also identified AMPy-
lated peptides for GLUD1 and TUBA1B (Table S4); however,
due to the incomplete peak assignment of the obtained
MS/MS spectra for these single peptide IDs (Fig. S5), they
were not included in the high-confidence substrate pool. Az-
RTB site ID methodology detected two high-confidence auto-
AMPylation sites on HYPE (Thr168 and Thr183, Fig. S4), and
these were further validated through AMPylation with isolated
HYPE E234G and ATP in place of Yn-6-ATP since the ab-
sence of a complex cellular lysate removes the need for
enrichment. The MS/MS searches were then executed in
analogous manner as for Az-RTB but taking advantage of
published masses for native AMP adduct formation and its
diagnostic ions (22, 23). We observed a total of 12 auto-
AMPylation sites (Table S5), including the two sites previously
assigned using Az-RTB methodology (Fig. S6), thus validating
Az-RTB as a robust tool for AMP site identification. Although
we did not succeed in detection of AMPylated peptides for all
the high-confidence substrates, our study provides a proof of
principle and a starting point for optimization of AMPylated
FIG. 2. Validation of AMPylation candidates. (A) Schematic diagram of the spike-in SILAC strategy used for substrate validation in terms
of dose-dependent HYPE and ATP enrichment specificity. (B) Heat maps of quantitative MS-based response of 25 high-confidence AMPylation
substrates to HYPE titration or ATP competition. Color coding represents normalized levels (five conditions normalized to 1:10 w/w enzyme
to lysate or 0 M ATP) of substrate AMPylation in response to a range of HYPE and ATP concentrations. Protein substrates are reported by
gene names. (C) Western blot validation of selected high-confidence substrates.
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peptide profiling (e.g. using additional modes of ion fragmen-
tation) and the first report of detection of AMPylated peptides
from multiple proteins that have undergone AMPylation in cell
lysates.
WT HYPE Interaction Partners In Vivo—The experiments
described above provide substantial and orthogonal evidence
for substrate validation in vitro; nevertheless, whether these
proteins are bona fide substrates in vivo remains a valid
question. Due to poor cell penetrance and competition with
endogenous ATP and nucleic acid biosynthetic pathways,
Yn-6-ATP is unlikely to be an effective tool to investigate
protein AMPylation in live cells; moreover, no alternative HT
methodology exists to facilitate such experiments. To link our
discovery in lysates with a more physiologically relevant en-
FIG. 3. Identification of AMPylation sites. (A) Structure of AMP-AzRTB derived adduct on Ser, Thr, or Tyr residues of AMPylated proteins
and respective diagnostic ions formed during MS/MS analysis. (B) Exemplary annotated MS/MS spectra of high-confidence assignments of
AMPylated peptides/sites (see Fig. S4 for other examples). MS/MS spectra for a given peptide were selected based on the highest probability
score (-10 lgP) assigned by PEAKS7. Diagnostic ions are framed. The asterisk (*) denotes loss of a fragment of diagnostic ion with delta mass
of 642.2018.
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vironment, we sought to determine whether high-confidence
substrates are also found as interacting partners of WT HYPE
in vivo. We utilized BirA (39), a bacterial biotin ligase, and WT
HYPE C-terminally tagged with a short BirA recognition se-
quence (WT-bio) in cotransfection experiments, allowing for
selective HYPE biotinylation in vivo and subsequent enrich-
ment together with its interacting partners. Accordingly, heavy
HEK293 cells were cotransfected with WT-bio and BirA,
whereas light cells were transfected with BirA only, to account
for any unspecific biotinylation, in biological duplicate (Fig.
S7). After mild cell lysis, biotinylated proteins were enriched
on NeutrAvidin agarose beads separately in heavy and in light
lysate, followed by beads mixing in 1:1 ratio, trypsin digest
and shotgun proteomics. H/L ratios for each protein were then
generated in MaxQuant, and quantification in both replicates
with log2 H/L ratios  1 was selected as the threshold for
protein assignments. First, we observed 8-fold H/L enrich-
ment for WT-bio (Table S6), which confirmed efficient
cotransfection and tagging by BirA in vivo. Secondly, ca.
fivefold enrichment was observed for the already reported (15)
HYPE substrate and interaction partner BiP (HSPA5) (Table
S6), validating this experimental approach. Furthermore, five
high-confidence substrates reported herein, including ATP
synthase subunits, tubulin chains, and elongation factor (Ta-
ble S6), also passed the selection criteria, suggesting that
they may indeed be novel bona fide HYPE substrates in vivo.
Functional Annotation of the Human AMPylome—Following
from the extensive validation of AMPylation substrates de-
scribed above, we carried out gene ontology (40) annotation
with The Database for Annotation, Visualization and Inte-
grated Discovery v6.7 (41) (Table S7) and functional classifi-
cation with Protein Analysis through Evolutionary Relation-
ships v10.0 (42) (Fig. 4). Analysis of the cellular compartment
domain (Fig. 4A) revealed propensity of AMPylation substrates
for cytoplasmic localization as well as for macromolecular com-
plex formation. Inspection of the molecular function domain
(Fig. 4B) indicated prevalence of terms in the binding category
with particular emphasis on protein, nucleotide, and RNA bind-
ing (Table S7). In addition, catalytic transporter as well as struc-
tural functions were also assigned. Within the biological process
domain (Fig. 4C), we noted that AMPylated substrates show
particular clustering within metabolic processes, including nu-
cleotide metabolism and biosynthesis (Table S7), as well as
transmembrane transport categories.
DISCUSSION
AMPylation is a novel type of PTM in eukaryotes, with
implications in essential cellular processes, including visual
neurotransmission (18), heat shock and unfolded protein re-
sponse (UPR) (14, 15), and potentially gene expression (17).
Our understanding of this modification is, however, in its
infancy since the number of known substrate proteins is strik-
ingly small. Although several strategies have evolved to gen-
erate substrate identifications in the context of bacterial
AMPylation (2, 26, 27), the scope of HYPE substrates has not
yet been revealed. Profiling eukaryotic AMPylation is chal-
lenging due to the low level of HYPE expression and its
autoinhibited state under physiological conditions. Moreover,
triggers allowing for release of this intramolecular inhibition to
yield catalytically active enzyme are currently unknown, as is
the prevalence of de-AMPylating enzymatic activities in the
cell. To overcome these obstacles, we performed chemopro-
teomic MS-based experiments in vitro utilizing a recombinant,
activated form of HYPE (E234G mutant) and Yn-6-ATP sub-
strate analogue (Fig. 1). This strategy allowed for efficient
enrichment and robust identification of 102 AMPylation can-
didates (Table S1) that were subsequently subjected to ex-
tensive and stringent validation in terms of enrichment spec-
ificity (Fig. 2) as well as AMPylation site assignments (Fig. 3
and Fig. S4), resulting in a pool of 25 high-confidence HYPE
substrates (Table S7), including the previously reported in vivo
substrate BiP (HSPA5). This finding not only validates chemo-
proteomic methodologies as reliable tools for HYPE AMPyla-
tion profiling but also demonstrates the link between studies
conducted in vitro and in vivo.
Apart from BiP, 24 identified proteins constitute novel sub-
strates of eukaryotic AMPylation reported here for the first
time. They represent mostly cytoplasmic proteins that can
associate with diverse cellular organelles, e.g. ER, nucleus,
and mitochondrion, and have a propensity to form larger
complexes (Fig. 4A, Table S7). The variety of molecular func-
tions and biological processes terms associated with the
FIG. 4. Functional classification of AMPylation substrates. (A) Distribution of cellular localization. (B) Distribution of molecular function. (C)
Distribution of biological processes. Analysis was performed on a pool of 25 high-confidence substrates with Protein Analysis through
Evolutionary Relationships classification tool.
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substrate pool (Figs. 4B and 4C, Table S7) significantly ex-
pands the previously reported repertoire of cellular phenom-
ena potentially affected by AMPylation (14, 15, 18). For ex-
ample, we identified several nuclear envelope proteins (NUP,
CACYBP, MATR3) responsible for binding/transport of RNA
and protein cargo across nuclear membranes and involved in
up-regulation of DNA replication. In addition, we detected
substrates (PABPC1, EWSR1, CTNND1, DDX5, DDX17) in-
volved in regulation of transcription as well as several sub-
strates (EEF1A, EIF2AK2, and LARP1) that participate in ac-
tivation/regulation of translation. Together, this evidence
strongly supports the previously suggested (17) involvement
of eukaryotic AMPylation in pathways of gene expression and
protein biosynthesis. Moreover, identification of substrates
such as ATP synthase catalytic core subunits (ATP5B,
ATP5A1) and further evidence for a direct interaction between
WT HYPE and this large protein complex in vivo (Table S6)
suggest that AMPylation may regulate ATP biosynthesis as
well as transport across the mitochondrial membrane. This
hypothesis is further corroborated by the identification of
SLC25A6, which is involved in ATP/ADP exchange between
mitochondria and the cytoplasm. Taken together, these re-
sults suggest a potential role of AMPylation in pathways in-
volved in oxidative phosphorylation and cellular metabolism.
Interestingly, it has been demonstrated that the UPR and
mitochondrial metabolism are closely associated via so-called
ER-mitochondrial coupling in the perinuclear space (43). This
microtubule-dependent phenomenon promotes increase in
mitochondrial respiration and ATP production during the on-
set of ER stress, providing favorable bioenergetics for chap-
erone expression and initiation of UPR. Identification of HYPE
substrates with roles in UPR, ATP biosynthesis/transport, and
gene expression as well as several members of the tubulin
family (TUBB, TUBB4B) that are major constituents of micro-
tubules provides interesting hypothesis that AMPylation by
HYPE could be an important regulator of ER stress in eukary-
otic cells. In addition, AMPylation of tubulins and potential
involvement in microtubule biology could point to further im-
plication of AMPylation in the maintenance of the cytoskele-
ton—an interesting perspective taking into account the fact
that bacterial AMPylation of Rho GTPases also targets the
cytoskeleton, with detrimental consequences for the infected
cell (44). Our experimental evidence clearly excludes small
GTPases as substrates of eukaryotic AMPylation in vitro, as
supported by recent reports under physiological conditions
(15) pointing to the conclusion that AMPylation is under strin-
gent control within the eukaryotic cell.
Molecular consequences of protein AMPylation involve bulk
and charge (–1) introduced by the AMP moiety and may affect
not only the substrate itself (stability, activity, cofactor bind-
ing) but also its interaction landscape. Only recently, molec-
ular consequences of HYPE-mediated AMPylation have been
elucidated in the context of ER chaperone BiP (HSPA5),
where modification with AMP in the vicinity of the ATPase
domain was shown to enhance its activity and had no effect
on binding of misfolded proteins (15). Interestingly, we de-
tected another AMPylation site on HSPA5, i.e. Thr518 (Fig. S4,
Table S4) within its substrate binding domain, and apart from
potential implications in the regulation of substrate binding,
this site is also targeted by phosphorylation (34). AMPylation
thus has potential to (reversibly or irreversibly) mask this
phosphosite, further substantiating a previously hypothesized
(27) crosstalk between these classes of PTM. In addition to
HSPA5, we confidently identified AMPylation sites on several
other substrates (Table S4), including EEF1A1 and TUBB4B
that were also identified herein as HYPE interaction partners
in vivo (Table S6). AMPylation of EEF1A1 at Thr261 within
domain 2, which is involved in binding to amino-acid-charged
tRNA (45), supports a role of this PTM in the regulation of
translation and gene expression as suggested above, while
AMP modification of TUBB4B within the GTPase domain
(Thr166) supports involvement of AMPylation in microtubule
dynamics.
In contrast to bacterial AMPylation, which has received
renewed interest in recent years, eukaryotic AMPylation and
its cellular substrates have remained largely unexplored, pre-
cluding elucidation of the biological phenomena that may be
regulated by this PTM. The results presented herein represent
not only the first objective, multifaceted, and quantitative ap-
proach for AMPylation profiling but also dramatically extend
the repertoire of HYPE substrates, delivering the first glimpse
of the scope of the human AMPylome. Our confident identi-
fications arising from extensive substrate validation by an
array of state-of-the-art quantitative chemoproteomic tech-
niques open new research avenues in the field of eukaryotic
AMPylation and provide a road map for substrate-targeted
investigations that will enable elucidation of specific conse-
quences of AMPylation for substrate structure, function, and
involvement in disease.
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Supplementary Figures  
Fig. S1. In gel fluorescence visualization of A)Time-dependence (1, 3, 5, 7, 20 h) of in vitro 
AMPylation with HYPE E234G; B) Substrate analogue Yn-6-ATP competition with increasing 
concentrations (0, 50, 200, 500, 1000 uM) of the natural substrate ATP. Protein loading is 
shown by Coomassie staining. AMPylation time of 3 h was selected for all experiments. 
 
 
 
Fig. S2. Schematic representation of SILAC-based identification of HYPE E234G 
AMPylation candidates. 
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Fig. S3. Mode of action for non-cleavable (Az-TB) and cleavable (Az-RTB) reagents. 
 
 
Fig. S4. MS/MS spectra of AMPylated peptides (high confidence assignments) detected 
using chemoproteomic approach and site ID reagent Az-RTB. MS/MS spectra for a given 
peptide were selected based on the highest probability score (-10lgP) assigned by PEAKS7. 
Diagnostic ions are framed. The asterisk (*) denotes loss of a fragment of diagnostic ion with 
delta mass of 642.2018. 
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Fig. S5. MS/MS spectra of incompletely annotated AMPylated peptides (single peptide IDs) 
detected using chemoproteomic approach and site ID reagent Az-RTB. MS/MS spectra for a 
given peptide were selected based on the highest probability score (-10lgP) assigned by 
PEAKS7. Diagnostic ions are framed. The asterisk (*) denotes loss of a fragment of 
diagnostic ion with delta mass of 642.2018 from the AMPylated fragment ion. 
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Fig. S6. MS/MS spectra of AMPylated peptides from HYPE E234G auto-AMPylation that 
were also found using Az-RTB site ID reagent (high confidence assignments). MS/MS 
spectra for a given peptide were selected based on the highest probability score (-10lgP) 
assigned by PEAKS7. Diagnostic ions are framed. The asterisk (*) denotes loss of a 
fragment of diagnostic ion with delta mass of 347.0626 from the AMPylated fragment ion. 
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Fig. S7. Schematic representation of SILAC-based identification of WT HYPE interaction 
partners in vivo.  
 
 
